ABSTRACT Introduction Molecular Glue Degraders (MGDs) is a concept that refers to a
class of compounds that facilitate the interaction between two proteins or molecules within a …

Targeted protein degradation has emerged as a transformative therapeutic modality for the
treatment of human diseases. The clinical successes of approved protein degraders like …

Drug-induced protein degradation is an emerging strategy for the inhibition of disease-
related inactivated proteins, which cannot be achieved by applying traditional inhibitors …

Targeted protein degradation is a promising area in the discovery and development of
innovative therapeutics. Molecular glues mediate proximity-induced protein degradation and …

We are excited to welcome you to our special Review issue in Cell Chemical Biology on
Advances and Opportunities in Targeted Protein Degradation. Over the past decade …

The evolution in research and clinical settings of targeted therapies has been inspired by the
progress of cancer chemotherapy to use small molecules and monoclonal antibodies for …

Targeted protein degradation is becoming a weapon of choice against targets considered
heretofore “undruggable.” Whereas most small molecules inhibit a protein by blocking its …

Molecular glue degraders (MGDs) are small molecules that degrade proteins of interest via
the ubiquitin–proteasome system. While MGDs were historically discovered serendipitously …

Molecular glue (MG) degraders are monovalent small molecule compounds that co-opt E3
ubiquitin ligases to target neo-substrates for proteasomal degradation. Here, we provide a …

Targeted protein degradation is a rapidly exploding drug discovery strategy that uses small
molecules to recruit disease-causing proteins for rapid destruction mainly via the ubiquitin …